Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.35 USD | -3.74% | -9.46% | +58.77% |
May. 03 | Wedbush Adjusts Geron's Price Target to $7 From $6, Keeps Outperform Rating | MT |
May. 02 | Geron Shares Decline After Q1 Loss Widens | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- Based on current prices, the company has particularly high valuation levels.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+58.77% | 2.06B | C+ | ||
+9.83% | 118B | B+ | ||
+10.80% | 106B | B+ | ||
-10.84% | 23.4B | B+ | ||
-1.69% | 22.1B | B | ||
-10.23% | 18.34B | A- | ||
-41.92% | 16.59B | A- | ||
-15.11% | 15.97B | B | ||
+6.62% | 14.03B | C+ | ||
+17.53% | 11.67B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GERN Stock
- Ratings Geron Corporation